TFRC and mucopolysaccharidosis type 2: Idursulfase beta [43], an anti-transferrin receptor antibody fused to iduronate-2-sulfatase based on J-Brain Cargo®, was clinically approved in Japan on 23 March 2021 for the treatment of Hunter syndrome.